- Home
- NUWE vs APVO Comparison
NUWE vs APVO Comparison
Compare NUWE & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- APVO
- Stock Information
- Founded
- NUWE 1999
- APVO 2016
- Country
- NUWE United States
- APVO United States
- Employees
- NUWE N/A
- APVO N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- APVO Health Care
- Exchange
- NUWE Nasdaq
- APVO Nasdaq
- Market Cap
- NUWE 3.9M
- APVO 3.3M
- IPO Year
- NUWE N/A
- APVO N/A
- Fundamental
- Price
- NUWE $0.96
- APVO $0.68
- Analyst Decision
- NUWE Strong Buy
- APVO Strong Buy
- Analyst Count
- NUWE 1
- APVO 1
- Target Price
- NUWE $17.00
- APVO $296.00
- AVG Volume (30 Days)
- NUWE 66.4K
- APVO 8.7M
- Earning Date
- NUWE 05-06-2025
- APVO 05-07-2025
- Dividend Yield
- NUWE N/A
- APVO N/A
- EPS Growth
- NUWE N/A
- APVO N/A
- EPS
- NUWE N/A
- APVO N/A
- Revenue
- NUWE $8,740,000.00
- APVO N/A
- Revenue This Year
- NUWE $22.96
- APVO N/A
- Revenue Next Year
- NUWE $29.97
- APVO N/A
- P/E Ratio
- NUWE N/A
- APVO N/A
- Revenue Growth
- NUWE N/A
- APVO N/A
- 52 Week Low
- NUWE $0.75
- APVO $0.60
- 52 Week High
- NUWE $12.60
- APVO $51.06
- Technical
- Relative Strength Index (RSI)
- NUWE 46.86
- APVO 30.50
- Support Level
- NUWE $0.86
- APVO $0.60
- Resistance Level
- NUWE $0.98
- APVO $0.80
- Average True Range (ATR)
- NUWE 0.07
- APVO 0.18
- MACD
- NUWE 0.01
- APVO 0.03
- Stochastic Oscillator
- NUWE 75.54
- APVO 5.52
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.